Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in Advanced GIST After Imatinib Failure
NCT04106024Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in gastrointestinal stromal tumor (GIST), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Progression-Free Survival at 18 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT04106024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04106024.